VANCOUVER, BC, June 15, 2023 /PRNewswire/ – Numinus Wellness Inc. (“Numinus”), (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and evidence-based investigational psychedelic-assisted therapies, announced a partnership with the Multidisciplinary Association for Psychedelic Studies (MAPS), to support psychedelic experiential opportunities for practitioners as…

Source

Previous articlePsychedelic Bulletin #139: Kentucky Earmarks $42m for Ibogaine Studies; Reunion Announces Take-Private Deal; Compass Patents Upheld; Theories of Psychedelics’ Mechanism of Action
Next articleIbogaine’s Surge in Popularity Could Be a Huge Loss for the Gabonese People Unless We Shift Course